Interleukin-28B Plays a Therapeutic Role on Mouse U14 Cervical Cancer Cells by Down-Regulating CD4+CD25+FoxP3+Regulatory T Cells In Vivo. Issue 8 (1st October 2015)

• Record Type: Journal Article
• Authors: Chen, Xiaoyun; Zhu, Bingdong; Luo, Yanping; Zhang, Dongdong; Zhang, Lang; Zhu, Huihui; Hao, Chunyan; Guo, Yuzhen; Liu, Huiling
• Is Part Of: International journal of gynecological cancer. Volume 25:Issue 8(2015:Oct.)
• Page Start: 1369
• Page End: 1376
• Publication Date: 2015-10-01
• Subjects: IL-28B -- Cervical cancer -- Regulatory T cells -- Immunotherapy -- U14 cell; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0000000000000528
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Aim: To investigate the immunotherapeutic effectiveness of adenoviral vector expressing mouse interleukin (IL)-28B (Ad-mIL-28B) against cervical cancer and its mechanism. Method: U14 cervical cancer cell–bearing mice were treated with Ad-mIL-28B. Meanwhile, whole cell vaccine was prepared by repeated freezing and thawing U14 cells. Then CD4 + CD25 + FoxP3 + regulatory T (Treg) cells were evaluated by flow cytometry. Tumor volume and metastasis in BALB/c and C57BL/6j mice were detected. Results: Ad-mIL-28B treatment significantly decreased the number of CD4 + CD25 + FoxP3 + Treg cells. Subsequently, there was a significant decrease in the size of tumor tissue and the numbers of heteromorphic tumor cells. The tumor metastasis in the lung and liver of the Ad-mIL-28B group also decreased. However, there was no therapeutic effect observed for whole cell vaccine on U14 tumor–bearing mice. Conclusion: Interleukin-28B can inhibit the growth and metastasis of cervical cancer in U14 tumor–bearing mice by down-regulating Treg cells.